AI-generated analysis. Always verify with the original filing.
InMed Pharmaceuticals Inc. announced the wind down of BayMedica LLC's commercial operations due to impending prohibitions under H.R. 5371 effective November 12, 2026, with completion targeted prior to June 30, 2026, incurring approximately $550,000 in severance costs and $120,000 in additional expenditures. Post-wind down, the Company will focus exclusively on pharmaceutical development including INM-901 for Alzheimer's and INM-089 for dry AMD.
Event Type
Disclosure
Mandatory
Variant
8-K
. 1 Item 7.01 Regulation FD Disclosure. On March 6 , 2026, the Company issued a press release regarding the Company’s wind down of commercial operations. A copy
of this Current Report, including Exhibit 99.2 attached hereto, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amen
. Financial Statements and Exhibits. (b) Pro forma financial information. The Company's unaudited pro forma condensed consolidated financial information giving